Welcome to Markets Desk, here's what's moving the conversation today.
Lululemon's growth story is getting a rewrite, and investors are paying attention. The athleisure giant is under pressure in North America, but its international business is quietly doing the heavy lifting. Some analysts believe that overseas momentum is compelling enough to see the stock triple by twenty thirty one, making geographic diversification the single thesis worth watching.
Shifting to biotech, Axsome Therapeutics is drawing fresh scrutiny after a pullback in its share price. The company has pushed several new drugs through to market over the past year, and early commercial results are showing genuine revenue traction. The question for investors right now is whether this dip represents a valuation reset or a genuine warning sign about execution ahead.
And in the AI infrastructure space, a story worth watching carefully involves data centers increasingly turning to so-called forever chemicals as a cooling solution for high-density AI workloads. A new report from chemical watchdog ChemSec flags the atmospheric release of these persistent compounds as a growing environmental liability, one that could invite regulatory scrutiny and reshape the cost calculus for hyperscale operators.
That's the tape. Markets Desk, signing off the floor.
